Related references
Note: Only part of the references are listed.Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
Oluwadolapo D. Lawal et al.
CIRCULATION (2023)
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis
Erica Villa et al.
JOURNAL OF HEPATOLOGY (2022)
Thromboembolism and bleeding in patients with atrial fibrillation and liver disease- A nationwide register-based cohort study Thromboembolism and bleeding in liver disease
Kamilla Steensig et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2022)
Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study
Marco Proietti et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis
Robert S. O'Shea et al.
GASTROENTEROLOGY (2021)
Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review
Yonghui Fu et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2020)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
Daniele Pastori et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver
Rohitash Jamwal et al.
MOLECULAR PHARMACEUTICS (2018)
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)